SynthesisBioMed research international2019

Safety and Efficacy in Relapsed or Refractory Classic Hodgkin's Lymphoma Treated with PD-1 Inhibitors: A Meta-Analysis of 9 Prospective Clinical Trials.

Xueyan Zhang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.